MAPT and Alzheimer disease: Growing evidence demonstrates a strong bidirectional relationship between Alzheimer's disease (AD) and metabolic dysfunction, with studies showing that AD patients exhibit cerebral insulin resistance that impairs glucose uptake necessary for synaptic function while simultaneously promoting amyloid‐β accumulation and tau hyperphosphorylation through activation of kinases like GSK‐3β (see Peng et al. 2024).